dupilumab (dupixent) Report issue

Biologics mAb Approved FDA First in Class Priority Review FDA

Active Ingredient History

NOW
  • Now
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as eczema, asthma and nasal polyps which result in chronic sinusitis.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$645.0496

United States

$1079.2200 - $3321.1506
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

dupilumab | dupixent | regn668 | regn-668 | sar231893

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue